IRIS
LOPALCO, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.410
AS - Asia 4.128
EU - Europa 2.921
SA - Sud America 1.059
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 17.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.226
SG - Singapore 1.806
BR - Brasile 830
CN - Cina 827
IT - Italia 551
HK - Hong Kong 477
FR - Francia 466
SE - Svezia 443
RU - Federazione Russa 434
DE - Germania 338
VN - Vietnam 300
FI - Finlandia 201
GB - Regno Unito 195
IN - India 145
BD - Bangladesh 92
AR - Argentina 87
CA - Canada 78
IQ - Iraq 75
ID - Indonesia 67
MX - Messico 66
TR - Turchia 58
ZA - Sudafrica 58
CI - Costa d'Avorio 49
JP - Giappone 46
ES - Italia 45
PK - Pakistan 43
BE - Belgio 34
CO - Colombia 34
EC - Ecuador 32
SA - Arabia Saudita 30
NL - Olanda 29
PL - Polonia 29
UA - Ucraina 28
VE - Venezuela 27
UZ - Uzbekistan 26
AT - Austria 24
MA - Marocco 22
CZ - Repubblica Ceca 21
CL - Cile 19
LT - Lituania 18
PH - Filippine 18
MY - Malesia 15
IE - Irlanda 14
PY - Paraguay 13
TN - Tunisia 12
KE - Kenya 11
IR - Iran 10
NP - Nepal 10
EG - Egitto 9
DO - Repubblica Dominicana 7
EU - Europa 7
JO - Giordania 7
KZ - Kazakistan 7
UY - Uruguay 7
AM - Armenia 6
AZ - Azerbaigian 6
CH - Svizzera 6
CR - Costa Rica 6
DZ - Algeria 6
ET - Etiopia 6
PA - Panama 6
PE - Perù 6
QA - Qatar 6
AE - Emirati Arabi Uniti 5
HN - Honduras 5
HR - Croazia 5
JM - Giamaica 5
KG - Kirghizistan 5
NI - Nicaragua 5
OM - Oman 5
SI - Slovenia 5
SN - Senegal 5
TH - Thailandia 5
BH - Bahrain 4
IL - Israele 4
LB - Libano 4
PT - Portogallo 4
RS - Serbia 4
AU - Australia 3
BB - Barbados 3
BO - Bolivia 3
GE - Georgia 3
HU - Ungheria 3
NG - Nigeria 3
PS - Palestinian Territory 3
RO - Romania 3
AF - Afghanistan, Repubblica islamica di 2
AL - Albania 2
BG - Bulgaria 2
DK - Danimarca 2
GA - Gabon 2
GH - Ghana 2
LU - Lussemburgo 2
LY - Libia 2
MD - Moldavia 2
ML - Mali 2
MM - Myanmar 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
ZW - Zimbabwe 2
Totale 17.699
Salva come PNG Salva come JPEG
Città #
Fairfield 1.069
Ashburn 1.062
Singapore 991
Woodbridge 692
Houston 654
Chandler 574
San Jose 534
Hong Kong 472
Seattle 446
Ann Arbor 390
Cambridge 387
Nyköping 364
Wilmington 329
Beijing 313
Dallas 212
Lauterbourg 186
Los Angeles 163
New York 146
Lawrence 125
Roxbury 120
Bari 112
Munich 112
Helsinki 106
Ho Chi Minh City 91
São Paulo 91
Jacksonville 85
Des Moines 79
Falkenstein 78
Nanjing 77
Buffalo 71
Santa Clara 68
Moscow 67
Inglewood 64
Council Bluffs 63
Hanoi 57
Princeton 57
Brooklyn 53
Abidjan 49
London 49
San Diego 45
Turku 42
Paris 39
Chicago 38
Jakarta 37
Frankfurt am Main 36
Johannesburg 36
Tokyo 36
Shenyang 35
Brussels 33
Milan 32
Dearborn 28
Belo Horizonte 27
Denver 27
Baghdad 26
Warsaw 25
Atlanta 24
Montreal 24
Boston 23
Dong Ket 23
Mexico City 23
Orem 23
Phoenix 23
Rio de Janeiro 23
San Francisco 22
Tashkent 22
Toronto 22
Manchester 21
Brasília 20
Nanchang 20
Pune 20
Chennai 19
Poplar 19
The Dalles 18
Columbus 17
Dhaka 16
Jiaxing 16
Stockholm 16
Redwood City 15
Boardman 14
Da Nang 14
Dublin 14
Guangzhou 14
Lahore 14
Salt Lake City 14
Tianjin 14
Changsha 13
Curitiba 13
Hebei 13
Nuremberg 13
Amsterdam 12
Campinas 12
Shanghai 12
Vienna 12
Goiânia 11
Guarulhos 11
Haiphong 11
San Mateo 11
Ankara 10
Augusta 10
Brno 10
Totale 11.941
Salva come PNG Salva come JPEG
Nome #
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 201
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 200
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 187
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 185
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 183
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis 179
Basic characteristics of adults with periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome in comparison with the typical pediatric expression of disease 178
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 175
Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study 174
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 169
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 167
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 165
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 165
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 164
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 161
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases 156
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 155
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 154
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 153
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 152
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 150
Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis 150
A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome 148
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 146
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 146
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study 145
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 143
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 142
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study 141
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 140
Serum amyloid-A in Behçet's disease 136
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 136
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 135
Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis 134
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 134
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate 133
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 133
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 131
Untangling the web of systemic autoinflammatory diseases 131
Explainable artificial intelligence for microbiome data analysis in colorectal cancer biomarker identification 128
Management of Small Vessel Vasculitides 128
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome 127
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 126
Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study 125
A convolutional neural network with transfer learning for automatic discrimination between low and high-grade synovitis: a pilot study 123
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 123
Critical regulation of Th17 cell differentiation by serum amyloid-A signalling in Behcet's disease 122
Improvement of Refractory Dysphagia in Patients with Idiopathic Inflammatory Myopathies Receveing Immunoglobulin Intravenous Therapy 121
Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. 120
Splenic Infarction as Only Manifestation of Antiphospholipid Syndrome in a Patient With Rheumatoid Arthritis 118
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 117
Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics 116
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 115
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 114
Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema 113
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 113
Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art 112
The autoinflammatory side of recurrent pericarditis: Enlightening the pathogenesis for a more rational treatment 112
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives 111
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings 110
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors 110
The protean ocular involvement in monogenic autoinflammatory diseases: state of the art 109
Pain Processing and Vegetative Dysfunction in Fibromyalgia: A Study by Sympathetic Skin Response and Laser Evoked Potentials 108
SAT0380 FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS 108
A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab 107
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 107
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study 107
Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet’s syndrome 106
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey 105
IL-6 blockade in the management of non-infectious uveitis 103
improvement of refractory dysphagia in patients with idiopathic inflammatory myopathies receveing immunoglubulin intravenous therapy 103
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 103
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 100
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis 99
Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series 99
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors 99
Anakinra effectiveness in refractory polyserositis: An Italian multicenter study 98
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry 97
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis 97
Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study 96
Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for behcet's disease 93
Genetic and clinical features of Familial Mediterranean Fever (FMF) in a homogeneous cohort of patients from south-eastern Italy 92
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study 92
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 90
Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis 90
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis 90
Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus 88
Complete Hydatidiform Mole Mimicking Sacroiliitis 88
Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients 87
null 86
Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade: a narrative review 86
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study 86
Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis 85
Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering 83
Effectiveness of Tapering Rituximab Dose in Idiopathic Inflammatory Myopathies: Real-World Data from a Monocentric Study 83
null 82
Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis 82
Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy 81
null 81
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease 81
Totale 12.358
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.089
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021332 0 0 0 0 0 0 0 0 0 142 99 91
2021/2022985 73 40 20 42 40 82 67 53 72 81 120 295
2022/20231.547 219 199 128 123 114 241 34 198 207 12 51 21
2023/2024545 41 107 24 44 48 129 18 28 6 15 13 72
2024/20252.950 66 37 197 64 47 279 318 347 151 201 439 804
2025/20266.983 908 311 466 969 1.174 473 793 249 862 778 0 0
Totale 18.671